Literature DB >> 12865310

Regulation of ovarian primordial follicle assembly and development by estrogen and progesterone: endocrine model of follicle assembly.

Phillip Kezele1, Michael K Skinner.   

Abstract

The assembly of the developmentally arrested primordial follicle and the subsequent transition of the primordial follicle to the primary follicle are critical processes in normal ovarian physiology that remain to be elucidated. Ovarian follicles do not proliferate and the primordial follicles present in the neonate represent the total number of gametes available to a female throughout her reproductive life. The primordial follicles are oocytes surrounded by less differentiated squamous granulosa cells and are derived from oocyte nests, and primary follicles are oocytes surrounded by a single layer of cuboidal granulosa cells that have initiated follicle development. Abnormalities in primordial follicle assembly, arrest, and development (i.e. primordial to primary follicle transition) can cause pathological conditions such as premature ovarian failure. In this study newborn rat ovaries were cultured for 7 d. The rate of primordial follicle assembly in vivo was identical with the rate in vitro. Interestingly, the rate of primordial follicle transition to the primary follicle was found to be 3 times greater in culture. This abnormal rate of primary follicle development in culture suggests the primordial follicle does not arrest in development as observed in vivo. To investigate this phenomena newborn rat ovaries were cultured in the presence of progesterone, estradiol or calf serum. Estradiol, progesterone, or calf serum significantly reduced the level of initial primordial to primary follicle transition. Approximately 60% of follicles make the primordial to primary follicle transition in control ovaries and about 30% in treated ovaries. Steroids and calf serum had no effect on the primordial to primary follicle transition in ovaries collected and cultured from postnatal 4-d-old rats, suggesting the effects observed are restricted to the initial wave of primordial to primary follicle transition. Interestingly, progesterone was also found to significantly reduce the rate of primordial follicle assembly. All viable oocytes assembled into primordial follicles in control ovaries and approximately 40% remained unassembled in progesterone-treated ovaries. Progesterone was also found to reduce primordial follicle assembly in vivo with 10% of the total follicles remaining unassembled in progesterone injected neonatal animals. Analysis of cellular apoptosis demonstrated that progesterone inhibited the coordinated oocyte apoptosis required for primordial follicle assembly. The hypothesis developed is that high levels of maternal and fetal steroids prevent premature primordial follicle assembly and primordial to primary follicle transition in the embryo. After birth steroid levels fall dramatically and the primordial follicles are free to assemble and initiate development. These observations suggest a novel role for steroids and the maternal-fetal endocrine unit in the control of ovarian primordial follicle assembly and early follicular development.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12865310     DOI: 10.1210/en.2002-0131

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  80 in total

Review 1.  Epigenetic effects of endocrine-disrupting chemicals on female reproduction: an ovarian perspective.

Authors:  Aparna Mahakali Zama; Mehmet Uzumcu
Journal:  Front Neuroendocrinol       Date:  2010-07-04       Impact factor: 8.606

Review 2.  Developmental exposure to environmental endocrine disruptors: consequences within the ovary and on female reproductive function.

Authors:  Mehmet Uzumcu; Rob Zachow
Journal:  Reprod Toxicol       Date:  2006-11-06       Impact factor: 3.143

Review 3.  The earliest stages of follicular development: follicle formation and activation.

Authors:  J E Fortune; M Y Yang; W Muruvi
Journal:  Soc Reprod Fertil Suppl       Date:  2010

Review 4.  The mammalian ovary from genesis to revelation.

Authors:  Mark A Edson; Ankur K Nagaraja; Martin M Matzuk
Journal:  Endocr Rev       Date:  2009-09-23       Impact factor: 19.871

5.  Bisphenol A exposure inhibits germ cell nest breakdown by reducing apoptosis in cultured neonatal mouse ovaries.

Authors:  Changqing Zhou; Wei Wang; Jackye Peretz; Jodi A Flaws
Journal:  Reprod Toxicol       Date:  2015-06-04       Impact factor: 3.143

6.  EGFR promotes the proliferation of quail follicular granulosa cells through the MAPK/extracellular signal-regulated kinase (ERK) signaling pathway.

Authors:  Yan Wu; Hongwei Xiao; Jinsong Pi; Hao Zhang; Ailuan Pan; Yuejin Pu; Zhenhua Liang; Jie Shen; Jinping Du
Journal:  Cell Cycle       Date:  2019-08-29       Impact factor: 4.534

7.  Suppression of Notch signaling in the neonatal mouse ovary decreases primordial follicle formation.

Authors:  Daniel J Trombly; Teresa K Woodruff; Kelly E Mayo
Journal:  Endocrinology       Date:  2008-09-25       Impact factor: 4.736

8.  Neutralization of vascular endothelial growth factor antiangiogenic isoforms is more effective than treatment with proangiogenic isoforms in stimulating vascular development and follicle progression in the perinatal rat ovary.

Authors:  Robin A Artac; Renee M McFee; Robyn A Longfellow Smith; Michelle M Baltes-Breitwisch; Debra T Clopton; Andrea S Cupp
Journal:  Biol Reprod       Date:  2009-07-15       Impact factor: 4.285

9.  Inhibition of vascular endothelial growth factor receptor signal transduction blocks follicle progression but does not necessarily disrupt vascular development in perinatal rat ovaries.

Authors:  Renee M McFee; Robin A Artac; Ryann M McFee; Debra T Clopton; Robyn A Longfellow Smith; Timothy G Rozell; Andrea S Cupp
Journal:  Biol Reprod       Date:  2009-07-15       Impact factor: 4.285

10.  Induction of ovarian primordial follicle assembly by connective tissue growth factor CTGF.

Authors:  Ryan Schindler; Eric Nilsson; Michael K Skinner
Journal:  PLoS One       Date:  2010-09-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.